85-6834-91　Theralizumab Biosimilar - Research Grade 50mg　ICH5023

特徴

• 背景：Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system’s T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.

仕様

• サイズ：50mg
• ターゲット：CD28
• 交差性：Human
• 精製方法：This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
• 濃度：5mg/ml
• 構成：Sterile, preservative-free, solution in PBS. BSA and Azide free.
• 純度：>95% by SDS-PAGE
• エンドトキシン：≤ 1.0 EU/mg as determined by the LAL method
• 適用：Functional Assays
• データシート：https://ichor.bio/product/Theralizumab-Biosimilar-Research-Grade-ICH5023?action=genpdf&id=81098
• この商品は法規制を確認しておりません。（法規制によって販売できない場合もございます）

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]